Skip to main content

Affiliate disclosure: We may earn a commission if you buy through links on this site — at no extra cost to you. Thanks!

Injection Safety · FDA Label–Verified · 2026

GLP-1 Injection Mistakes to Avoid — and Exactly What to Do When You've Made One

By WPG Research Team·Last verified: May 7, 2026·Against current FDA and DailyMed prescribing information and IFUs for Wegovy, Ozempic, Zepbound, Mounjaro, Trulicity, and Saxenda.
This guide is for general informational purposes based on FDA-approved labeling. It does not constitute medical advice. Contact your prescriber, pharmacist, or Poison Help (1-800-222-1222) for clinical decisions.

Bottom line

Most GLP-1 injection mistakes are small. The ones with real label-verified safety risk cluster in a tight group — drawing the wrong dose from a compounded vial, taking doses too close together or doubling up after a shot felt off, using a pen or vial the label says to throw away, and restarting at maintenance dose after missing two or more weeks. Site rotation, cold injection, and not pinching skin affect comfort, not safety. This guide ranks every common mistake by what actually causes harm and gives you the exact fix for each one.

Pick what just happened — fast triage

If you're reading this five minutes after an injection that didn't go the way you expected, jump straight to the section that fits:

Severe symptoms after a dose mistake?

Call Poison Help at 1-800-222-1222 or seek emergency care. Free, 24/7, staffed by trained nurses, pharmacists, and doctors. Per HRSA, callers speak directly with a clinical professional at their local poison center.

Which GLP-1 products this guide covers

WegovyOzempicZepboundMounjaroTrulicitySaxendaCompounded semaglutide / tirzepatide

This guide does not cover Byetta, Bydureon BCise, Victoza, Adlyxin, Soliqua, Xultophy, or oral products (Rybelsus, Wegovy tablets). Check your specific Medication Guide before applying any rule from this page to those products.

The 13 GLP-1 injection mistakes to avoid — ranked by what actually hurts you

Quick answer: Not all GLP-1 injection mistakes are equal. Drawing the wrong dose from a compounded vial, using a damaged or out-of-storage pen, injecting into muscle while on insulin or a sulfonylurea, and doubling up after a missed dose are the high-risk mistakes. Site rotation, cold injection, and skin-pinching are low-risk and mostly affect comfort.

This is an editorial risk tier — not a clinical trial finding. Built from three source buckets: FDA-documented compounded-GLP-1 dosing errors and adverse-event reports, FDA-approved label warnings, and Poison Centers exposure patterns.

TierWhat it isWhy it's at this tier
Tier 1 — High risk
  1. Drawing the wrong dose from a compounded vial
  2. Using a pen or vial the label says to throw away (frozen, exposed above 86°F, visibly damaged)
  3. Injecting into muscle while also taking insulin or a sulfonylurea
  4. Taking a second shot when you're not sure the first went in
  5. Restarting at maintenance dose after missing two or more weeks
FDA-documented dosing errors and hospitalizations; label-mandated discard rules; hypoglycemia risk with combination therapy
Tier 2 — Medium risk
  1. Skipping the slow dose escalation (titration) schedule
  2. Using another brand's missed-dose rule
  3. Injecting into a lump (lipohypertrophy)
  4. Pulling the needle out before the dose finishes
  5. Reusing or sharing needles
Reduced effectiveness, worse side effects, infection risk, unpredictable absorption
Tier 3 — Comfort / minor
  1. Injecting cold straight from the fridge
  2. Repeatedly using the exact same spot inside one body region
  3. Injecting through clothing (not label-supported — IFUs say to clean dry skin)
Affects comfort or absorption modestly, not safety
Tier 1 — High risk

Mistake 1: Drawing the wrong dose from a compounded vial — the FDA's GLP-1 dosing-error alert

Quick answer: The FDA has issued a public safety alert about compounded semaglutide dosing errors that caused hospitalizations. Patients injected up to 5 to 20 times their intended dose because they confused milligrams (mg), milliliters (mL), and "units" on a U-100 insulin syringe.

Compounded GLP-1s come from compounding pharmacies — facilities that mix custom medications. They are not FDA-approved and the concentration printed on the vial can vary between refills and between pharmacies. That's where the danger lives.

The prescribed dose is in milligrams, the vial is labeled in milligrams per milliliter, and the insulin syringe is marked in "units." Three different units of measurement that don't translate to each other without the specific concentration of the vial in your hand. If the concentration changes between refills — and it often does — the same number of units delivers a different amount of medication. The FDA documented some patients drawing 50 units when their prescriber meant 5 — a tenfold overdose.

How to actually fix this

Read these two lines off your vial label every single time, before every injection:

1

The medication and concentration — e.g., "semaglutide 5 mg/mL" or "tirzepatide 17 mg/mL."

2

The exact units to draw for your prescribed dose — must match the chart your dispensing pharmacy gave you for this specific vial.

If those two numbers don't match the chart — stop. Don't inject. Call the dispensing pharmacy.
Why we flag this so hard: As of July 31, 2025, the FDA had received 605 adverse event reports associated with compounded semaglutide and 545 associated with compounded tirzepatide — likely undercounted, as many state-licensed pharmacies are not required to submit to the FDA. The semaglutide injection shortage was officially resolved February 21, 2025; tirzepatide on December 19, 2024. The FDA has proposed placing semaglutide, tirzepatide, and liraglutide on the 503B bulks list (April 30, 2026 proposal; comments invited through June 29, 2026). If finalized, that would restrict which compounders can produce them.
Tier 1 — High risk

Mistake 2: Using a pen or vial the label says to throw away

Quick answer: If a pen or vial has been frozen, exposed above the label's temperature limit, or appears cloudy, particulate, discolored, or visibly damaged, follow the label and don't use it. Trying to "thaw and use" a pen that froze can mean injecting medication that won't work — wasting a week of treatment without knowing it.

Every manufacturer says the same thing: discard if frozen, even after thawing. Visible particles or discoloration is also a discard trigger across all labels.

What to look at before every shot

Clear and colorless (or very slightly yellow for some brands) → proceed
Cloudy, hazy, or milky → throw it out
Visible particles or specks → throw it out
Discolored or brownish → throw it out
Frozen, partly frozen, or thawed-from-frozen → throw it out
Cracked pen, leaking around the cap, or visible damage → throw it out and call the manufacturer
Practical tip: If the pen was in a car, mailbox, suitcase, or direct sun, don't try to estimate from the outside temperature. Write down the time and approximate conditions and call the dispensing pharmacist or the manufacturer. Most insurers and cash-pay programs will replace medication stored incorrectly through no fault of yours — but only if you ask.
Tier 1 — High risk

Mistake 3: Injecting into a muscle when you're also on insulin or a sulfonylurea

Quick answer: GLP-1 injections are subcutaneous — they go into the layer of fat just under the skin. Hitting muscle accidentally usually causes more pain and bruising and can make the medication absorb faster than expected. For people also taking insulin or a sulfonylurea (glipizide, glyburide), faster absorption can drop blood sugar low enough to cause hypoglycemia.

How to make sure you're hitting fat, not muscle

  • 1Use the abdomen, the front of the thigh, or the back of the upper arm. Avoid the inner thigh, buttocks, and any area where you can't easily feel a soft layer of subcutaneous fat.
  • 2For people on the leaner side, pinch the skin gently. Lift a fold and inject into the fold at a 90-degree angle. The fold puts the fatty tissue between you and the muscle.
  • 3For people with more abdominal fat, no pinch needed for a standard short pen needle.
  • 4Inject straight in (90 degrees), not at an angle, unless your provider specifically taught you a different technique for a thinner site.
If you use insulin or a sulfonylurea and you think the injection went into muscle — or you start to have low-blood-sugar symptoms (sweating, shakiness, confusion, fast heartbeat) — contact your prescriber and follow your diabetes low-blood-sugar plan. Treat hypoglycemia with fast-acting sugar (glucose tablets, juice, regular soda) and call for help if it doesn't resolve.
Tier 1 — High risk

Mistake 4: Taking a second shot because the first one "felt wrong"

Quick answer: If a shot didn't feel right, do not automatically inject again. Some medication may already be in your body, and there's no reliable way to measure how much from looking at your skin. Check the pen's completion indicator, document what happened, and call your pharmacist, prescriber, or Poison Help. A second injection on top of an unknown amount is a real overdose risk.

GLP-1 overdoses produce predictable symptoms: severe nausea, severe vomiting, severe diarrhea, dehydration, and in people on insulin or a sulfonylurea, hypoglycemia. Semaglutide has a half-life of about 7 days; tirzepatide roughly 5 days — the effects of an overdose can last for a week or more.

Device completion cues — check this first

Wegovy:Watch the yellow bar in the medication window. Dose finished when the yellow bar stops moving. If the bar moved fully, you got the dose.
Ozempic:Check the dose counter after pressing the button. Counter should read "0." Count slowly to six with needle in skin. If you removed needle before "0" appeared, some dose was lost.
Trulicity:Listen for the second click. First click = start. Second click (5–10 sec later) = finish. One click = incomplete.
Mounjaro / Zepbound single-dose pen:Look for the gray plunger. Dose delivered when the gray plunger is visible at the bottom of the medication window. No gray plunger → call Lilly (1-800-545-5979).
Saxenda:Dose counter (not the clicks). Counter returns to 0 and you count to 6 with needle in skin. The IFU specifically warns against counting clicks.
Compounded vial / insulin syringe:Plunger and barrel. Dose finished when plunger is fully seated and barrel is empty. Liquid still in barrel = incomplete.

Then write down what happened, and call

Document: medication name, time of injection, what the device did, what symptoms you have, how much liquid (if any) you saw on your skin. Take a photo of the pen if it might be defective.

Wegovy

1-833-934-6891

Novo Nordisk

Ozempic

1-866-696-4090

Novo Nordisk

Saxenda

1-844-845-6913

Novo Nordisk

Mounjaro · Zepbound · Trulicity

1-800-545-5979

Eli Lilly (1-800-LILLYRX)

Do not inject a second dose unless they tell you to.

The full GLP-1 storage and missed-dose chart

Built from FDA labels via DailyMed and manufacturer IFUs. Last verified May 7, 2026. GLP-1 storage and missed-dose rules are not interchangeable across brands — using the wrong brand's rule is Tier 2 mistake #7.

MedicationActive ingredientScheduleRefrigerated storageRoom-temp limitOnce at room tempMissed-dose ruleSource
Wegovy single-dose pen (incl. HD 7.2 mg)semaglutideWeekly36–46°F (2–8°C) until expirationUp to 86°F for 28 days total, before cap removal, in original cartonMay return to refrigerator within the 28-day totalNext dose >48 hrs away → take it. <48 hrs → skip. 2+ doses missed → resume on schedule or reinitiate dose escalation.DailyMed Wegovy label; Wegovy IFU
Ozempic multi-dose pensemaglutideWeekly36–46°F until first useAfter first use: 56 days at 59–86°F (15–30°C) or refrigeratedAfter first use, may store at room temperature or refrigerated for the 56-day in-use windowWithin 5 days of scheduled dose → take it. After 5 days → skip.DailyMed Ozempic label
Mounjaro / Zepbound single-dose pen or vial⚠ See callout belowtirzepatideWeekly36–46°F until expirationUp to 86°F for a total of 21 days — discard after 21-day total, even if put back in fridgeRefrigerating again does not reset the 21-day totalWithin 4 days (96 hrs). Do not take 2 doses within 3 days.DailyMed Mounjaro / Zepbound label
Mounjaro / Zepbound multi-dose vial or KwikPentirzepatideWeekly36–46°F until first useAfter first use: 30 days at room temp or refrigerated. Discard after 30-day total, 30 days after first use, or after 4 weekly doses — whichever comes firstRefrigerating does not reset the 30-day totalWithin 4 days (96 hrs). Do not take 2 doses within 3 days.DailyMed Mounjaro / Zepbound multi-dose label
Trulicity single-dose pen⚠ See callout belowdulaglutideWeekly36–46°F until expirationUp to 86°F for a total of 14 days — shortest of all products covered hereRefrigerating does not reset the 14-day totalTake if ≥3 days (72 hrs) remain before next dose. Otherwise skip.DailyMed Trulicity label
Saxenda multi-dose penliraglutideDaily36–46°F until first useAfter first use: up to 86°F for 30 days, or refrigeratedAfter first use, may store at room temp or refrigerated for the 30-day in-use windowResume next scheduled daily dose; no extra dose. If >3 days lapsed, restart at 0.6 mg daily and re-escalate per label/prescriber.DailyMed Saxenda label
Compounded semaglutide / tirzepatide vialvariesPer prescriberPer pharmacy label (typically 36–46°F)Per pharmacy beyond-use datePer pharmacyPer prescriber's schedule (no FDA-uniform rule — not FDA-approved)FDA: Concerns with Unapproved GLP-1 Drugs

Wegovy gets 28 days at room temperature. Mounjaro and Zepbound single-dose pens get 21. If you switched from Wegovy to Zepbound and you're still using the 28-day rule, you could be using a pen that's a week past its safe room-temperature window.

For Mounjaro, Zepbound, and Trulicity, the room-temperature window is a total clock. Putting the pen back in the fridge does not reset the count. Total time at room temperature must stay under 21 days (Mounjaro/Zepbound single-dose), 30 days (Mounjaro/Zepbound multi-dose), or 14 days (Trulicity).

Trulicity has a 14-day room-temperature limit — the shortest of the products covered here. People assume "all GLP-1s are 21 or 28 days." Trulicity isn't.

Ozempic's 56-day in-use rule is unique. Once you start it, you have 56 days — whether stored at room temperature or refrigerated — before you must throw it away, even if medication remains.

Saxenda is daily, not weekly. Different missed-dose math entirely.

Compounded products follow no uniform FDA rule. Whatever your pharmacy printed on the label is the rule.

What to do if your medicine leaked or the pen seemed to misfire

Quick answer: If you see a drop of medication on your skin after the needle comes out, some dose may already be in your body — but there's no reliable way to measure how much. Do not inject again. Check the pen's completion indicator. Document what happened and call the manufacturer's product line if you're not sure how much dose was delivered.
ProductWhat to checkWhat it means
WegovyThe yellow bar in the medication windowDose finished when the yellow bar stops moving. If you removed the pen before the bar finished, some dose was lost.
OzempicDose counter and 6-second holdDose finished when counter shows "0" and you hold needle in skin for six seconds. A stream on your skin after withdrawal means you pulled too early.
TrulicityTwo clicks (start and finish)Dose finished when the second click happens, about 5–10 seconds after the first. One click = incomplete.
Mounjaro / Zepbound single-dose penThe gray plungerDose finished when the gray plunger is visible at the bottom of the medication window. No gray plunger = call Lilly.
SaxendaDose counter (not the clicks)Dose finished when counter returns to 0 and you've counted slowly to 6 with needle in skin. IFU warns specifically against counting clicks.
Compounded vial / insulin syringePlunger and barrelDose finished when plunger is fully seated and barrel is empty. Liquid still in barrel = incomplete.

Small drop of blood at the site

You hit a tiny surface vessel — normal. Press lightly with gauze or cotton; do not rub. The dose still went in.

Small drop of medication on your skin

A small amount of dose was lost. Don't try to estimate how much. Note it in your records and use the full hold time on your next injection.

When to call

  • The dose counter or completion indicator didn't behave as expected
  • The pen feels jammed, the needle looks bent, or the device looks visibly damaged
  • You see a large stream of liquid on your skin after withdrawing
  • You're not sure how much dose you got — especially if you're considering injecting again

What to do if you accidentally took two doses

Quick answer: Treat an accidental double dose as a possible overdose. GLP-1 overdoses cause severe nausea, severe vomiting, dehydration, and in people on insulin or sulfonylureas, hypoglycemia. Call your prescriber. If symptoms are severe, call Poison Help at 1-800-222-1222 or seek emergency care.
1

Don't panic

A doubled GLP-1 dose is uncomfortable, but for most people without other risk factors it's manageable with monitoring.

2

Hydrate aggressively

Sip water and electrolytes throughout the day. Severe vomiting and diarrhea cause dehydration faster than people expect.

3

Check your blood sugar more often than usual

If you're also on insulin, a sulfonylurea, or any other diabetes medication. Hypoglycemia is the hidden danger.

4

Call your prescriber's office

Tell them what happened, what you took, when, and what symptoms you have.

5

Watch for severe symptoms

Severe abdominal pain that radiates to your back (possible pancreatitis), persistent vomiting, signs of dehydration, fainting, or low blood sugar that doesn't respond to fast-acting sugar — any of these means you need to be seen urgently.

6

Call Poison Help (1-800-222-1222) or go to the ER if symptoms escalate

Per America's Poison Centers, GLP-1 mistakes including taking doses too close together or higher than the recommended amount are routinely handled by Poison Help.

What not to do

  • Don't fast or skip food — empty stomach plus extra GLP-1 is a recipe for worse nausea
  • Don't take more medication
  • Don't take your next scheduled dose without calling your prescriber to figure out the correct restart timing
  • Don't crowdsource a treatment plan from social media

What to do if you missed a dose — rules differ by brand

Quick answer: There is no universal missed-dose rule for GLP-1 medications. Wegovy uses a 48-hour window. Ozempic uses 5 days. Mounjaro and Zepbound use 4 days (96 hours). Trulicity uses 3 days (72 hours). Saxenda is daily and has its own restart rules. Doubling up to "catch up" is not approved by any FDA label.
MedicationIf you remember within…What to doSource
WegovyNext dose >48 hours awayTake the missed dose now. Resume schedule.DailyMed Wegovy label
WegovyNext dose <48 hours awaySkip. Take next dose on schedule.DailyMed Wegovy label
Ozempic5 days of scheduled doseTake it now. Resume regular schedule.DailyMed Ozempic label
OzempicMore than 5 daysSkip. Take next dose on regular day.DailyMed Ozempic label
Mounjaro / Zepbound4 days (96 hours) of scheduled doseTake it now. Then wait at least 3 days before next dose.DailyMed Mounjaro / Zepbound label
Mounjaro / ZepboundMore than 4 daysSkip. Take next dose on regular day.DailyMed Mounjaro / Zepbound label
TrulicityAt least 3 days (72 hours) before next doseTake the missed dose.DailyMed Trulicity label
TrulicityLess than 3 days before next doseSkip.DailyMed Trulicity label
Saxenda (daily)Same day or nextResume the once-daily regimen with the next scheduled dose. Do not take extra dose.DailyMed Saxenda label
Saxenda (daily)More than 3 days lapsedRestart at 0.6 mg daily and re-escalate per label. Call prescriber.DailyMed Saxenda label
What if you missed two or more weeks? The Wegovy label has explicit reinitiation language: resume on the regularly scheduled day or, if needed, reinitiate and follow the dosage escalation schedule. Saxenda has explicit restart language (restart at 0.6 mg). For Mounjaro/Zepbound outside the 4-day window — and for Ozempic and Trulicity after extended interruptions — call the prescriber before restarting.
"I'll just double up next week" — This is not approved by any FDA label for any GLP-1. Doubling a weekly dose roughly doubles the side effects without recovering the lost week. Skip the missed dose, resume on schedule.
Changing your weekly injection day: For Ozempic, at least 2 days (48 hrs) must have passed since the last dose. For Mounjaro and Zepbound, at least 3 days (72 hrs) must have passed. Don't squeeze two doses inside those minimums.

Where to inject — and how to actually rotate sites

Quick answer: All six injectable products covered here use subcutaneous injection in the abdomen, the front of the thigh, or the back of the upper arm. Mounjaro and Zepbound labels specify that another person should inject the back of the upper arm. "Rotating sites" means changing the exact spot, not necessarily the whole body region. Repeated injections in the exact same spot can cause lipohypertrophy — thickened, lumpy tissue.

The quadrant method — the actually useful version of "rotate sites"

Divide your abdomen into four quadrants — like four squares around your belly button (avoiding the 2-inch radius around the belly button, per the Wegovy IFU).

Quadrant 1 — Week 1
Quadrant 2 — Week 2
Quadrant 4 — Week 4
Quadrant 3 — Week 3

Then go back to quadrant one — but at least an inch or two from where you injected four weeks ago. This gives every spot at least four weeks to recover. The same principle applies if you alternate between abdomen, thigh, and arm — the unit you're rotating is the spot, not the body region.

Where not to inject

  • Within 2 inches of the belly button (per Wegovy IFU — reasonable rule for any abdominal injection)
  • Bruised, red, hard, swollen, tender, scarred, or stretch-marked skin
  • Any visible lump (lipohypertrophy)
  • The buttocks (not approved for any GLP-1 — that's for IM injections)
  • The inner thigh (less consistent fat layer, more variable absorption)

The pre-injection checklist we wish every prescriber handed out

Quick answer: A consistent five-step pre-shot checklist prevents most GLP-1 injection mistakes before they happen. Built from the pre-injection steps explicitly listed in the FDA-approved IFUs for all six products covered here.
1

Confirm

  • Wash your hands
  • Confirm the medication name on the label matches your prescription
  • Confirm the dose strength matches what your prescriber wrote
  • Confirm today is your scheduled injection day
  • Check the expiration date on the carton and on the pen
  • If using a compounded vial: confirm the concentration printed on this specific vial matches the dose chart from your dispensing pharmacy
2

Inspect the solution

  • Hold the pen up to a light and look through the medication window
  • Solution is clear and colorless (or very slightly yellow, depending on brand)
  • No cloudiness, particles, or discoloration
  • No signs the medication has been frozen
  • If anything looks off — throw the pen out and use a new one
3

Prepare the device

  • Attach a new needle (for multi-dose pens that require it, like Ozempic and Saxenda)
  • For a brand-new pen: do the priming or flow check the IFU specifies before the first injection
  • Set the dose, if your pen has a dose dial
  • Confirm the dose counter shows the prescribed amount
4

Inject

  • Choose a clean, unlumped injection site in your weekly rotation
  • Wipe the skin with an alcohol swab and let it dry fully (injecting through wet alcohol stings)
  • Pinch the skin gently if you're thinner; skip the pinch if you have more abdominal fat
  • Insert the needle straight in (90 degrees) and press the dose button
  • Hold for the required time per your device's completion indicator
  • Withdraw the needle slowly
5

Document and dispose

  • Write down date, time, dose, site, and any notes
  • Drop the used needle (or the whole single-dose pen) into an FDA-cleared sharps container immediately
  • Set your reminder for next week's injection

Sharps and needles — the rules nobody told you

Quick answer: Used GLP-1 needles and pens are biohazardous sharps. The FDA recommends FDA-cleared sharps disposal containers and warns against throwing loose sharps in household trash, flushing them, or putting them in recycling. The CDC injection-safety rule is "One Needle, One Syringe, Only One Time."

Use

  • FDA-cleared sharps disposal container (puncture-resistant, leak-proof, labeled)
  • When FDA-cleared container unavailable: heavy-duty plastic household container with tight, puncture-resistant lid, labeled "USED SHARPS — DO NOT RECYCLE"

Never use

  • Soda bottles (too thin)
  • Glass jars (break easily)
  • Coffee cans (rust and leak)
  • Plastic shopping bags (no puncture resistance)

Where to take the full container

  • Drop-off at a participating pharmacy or hospital
  • Mail-back program (some manufacturers offer one)
  • Hazardous-waste collection day in your community
  • State household sharps program — check your state health department
The reuse rule: The CDC's "One Needle, One Syringe, Only One Time" isn't about caution — it's about not transmitting infections and not contaminating the next dose. For multi-dose pens (Ozempic, Saxenda): attach a new needle every time; remove and discard the needle after each injection before storing the pen. Never share pens — the Ozempic label is explicit: pens are for single-patient use and "should never be shared, even if the needle is changed."

Counterfeit and "research-use" GLP-1s — the unsafe shortcut

Quick answer: The FDA warns consumers not to purchase GLP-1 products labeled "for research purposes" or "not for human consumption." The FDA has also alerted consumers about counterfeit Ozempic in the U.S. supply chain. The FDA has specifically warned that retatrutide and cagrilintide cannot be used in compounding under federal law. Buy GLP-1 medications only from state-licensed pharmacies with a real prescription.

How to know what you're getting

  • A real prescription from a real prescriber
  • A state-licensed pharmacy (you can verify with the state board of pharmacy)
  • Medication that arrives sealed, with manufacturer labeling, in temperature-controlled packaging
  • A pharmacist you can call with questions

If any of those four are missing, you're taking a different kind of risk than the one this guide can fix.

When to call for help — and which number

Call your prescriber

  • Side effects interfering with your life but not severe
  • A dose mistake where you're not sure what to do next
  • Any new symptom you're not sure about
  • A device that's behaving oddly

Call the manufacturer

Wegovy1-833-934-6891
Ozempic1-866-696-4090
Saxenda1-844-845-6913
Mounjaro · Zepbound · Trulicity1-800-545-5979

Call Poison Help — 1-800-222-1222

  • Confirmed or suspected overdose
  • Severe symptoms after a dose mistake — especially severe vomiting, dehydration, hypoglycemia, or fainting
  • You need a clinical professional on the phone right now and your prescriber's office is closed

Free, 24/7. Per HRSA, callers speak with a specially trained nurse, pharmacist, or doctor at their local poison center.

Go to the ER

  • Severe abdominal pain that radiates to the back (possible pancreatitis)
  • Persistent vomiting that won't stop
  • Hypoglycemia symptoms that don't resolve with fast-acting sugar
  • Difficulty breathing, swelling of the face/lips/tongue, or hives (possible allergic reaction)
  • Signs of severe dehydration (dizziness on standing, very low urine output, confusion)
  • Fainting

When your provider is part of the problem

Disclosure: this section includes affiliate links. We may earn a commission if you choose a provider we mention. This does not change our editorial recommendations. Clinical guidance throughout this page is sourced from the FDA labels and sources cited in the verification section — not from affiliate relationships.
Quick answer: Many patient-side GLP-1 mistakes are downstream of provider-side mistakes — prescribing without a clear titration plan, dispensing compounded vials without a printed concentration sheet, or being unreachable when something goes wrong. If your current provider does any of those, the safest fix isn't better technique. It's a provider with a tighter protocol.
1

Sign #1: No titration plan in writing

Every FDA-approved GLP-1 has a step-up dosing schedule. If your provider started you at maintenance dose to "speed up results," or didn't write down what week you should move from one dose to the next, that's not aggressive medicine. It's a clinical red flag.

2

Sign #2: Compounded vial without a printed concentration sheet

If your dispensing pharmacy didn't give you a printed page that says "your vial is X mg/mL, draw Y units on the syringe we sent to get Z mg," you are doing the math without a checked source.

3

Sign #3: Can't get a pharmacist or clinician on the phone reasonably quickly

If you're holding a vial you're not sure about and there's no one to call, the safety system has failed.

What a good GLP-1 provider does

  • Provides a written titration plan that covers every dose for the next 16 weeks
  • For compounded medications, sends a printed concentration sheet with every refill, plus a syringe sized to the dose
  • Has a real phone number that gets answered by a pharmacist or clinician promptly
  • Re-titrates after missed weeks instead of resuming at maintenance
  • Doesn't gate-keep anti-nausea support or charge it as an upsell

FDA-approved GLP-1 + insurance navigation

Ro

Integrates with manufacturer patient programs for Wegovy, Ozempic, Zepbound, and Mounjaro. Runs a structured titration protocol. Free GLP-1 insurance coverage check.

Check GLP-1 Access on Ro →

Cash-pay transparent pricing

Sesame Care

Transparent cash pricing for office visits and prescriptions when insurance doesn't cover the brand. Multiple clinician options on one marketplace.

Browse GLP-1 Providers on Sesame →

We have not independently audited their compliance with every item on the safety checklist above. Run the checklist yourself before signing up with any provider — including the ones we work with.

Frequently Asked Questions

Drawing the wrong dose from a compounded vial. The FDA has documented dosing errors, some requiring hospitalization, where patients took up to 5 to 20 times the intended amount because they confused milligrams (mg), milliliters (mL), and "units" on an insulin syringe.

No. Some medication may already be in your body. Check the pen's completion indicator — the yellow bar on Wegovy, the dose counter on Ozempic and Saxenda, the second click on Trulicity, and the gray plunger on Mounjaro/Zepbound single-dose pens. If you're not sure how much went in, call the product's support line or your prescriber. Don't inject again on assumption.

Not feeling the needle is normal — many GLP-1 pen needles are very short and thin. Whether the dose went in is determined by the pen's completion indicator, not by what you felt.

No. Repeated injections in the exact same spot can cause lipohypertrophy — thickened tissue that may make absorption less predictable. Use the quadrant method: divide each body region into four spots and rotate weekly.

Manufacturer pharmacokinetic data shows similar exposure across the approved sites for semaglutide. Most people choose the abdomen because it's easiest to reach. Some patients report fewer GI side effects from the thigh; if your nausea is bad after abdominal injections, the thigh is worth discussing with your prescriber.

At least 2 inches, per Wegovy's Instructions for Use. This is a reasonable rule for any abdominal GLP-1 injection.

If your next dose is more than 48 hours away, take it now. If it's less than 48 hours away, skip and take the next dose on schedule. If you've missed two or more weeks, the label allows resuming on the regularly scheduled day or, if needed, reinitiating with the dose escalation schedule — call your prescriber to confirm which is right for you.

Take it within 5 days of your scheduled injection. After 5 days, skip and take the next dose on schedule.

Take it within 4 days (96 hours). After that, skip. Don't take two doses within 3 days of each other.

Take it if at least 3 days (72 hours) remain before your next scheduled dose. Otherwise, skip.

Saxenda is daily. Resume the once-daily regimen with the next scheduled dose; do not take an extra dose to make up for the missed one. If more than 3 days have lapsed, restart at 0.6 mg per the FDA label and call your prescriber to re-escalate.

No. The CDC rule is "One Needle, One Syringe, Only One Time." Reusing dulls the needle, increases infection risk, and can cause partial doses if the needle bends or blocks.

Throw it out, even if it thawed and looks fine. Every FDA-approved GLP-1 label says to discard if frozen. Frozen products can change in ways that aren't always visible.

Stop. Don't inject again until you've spoken to the dispensing pharmacist. Document what you drew and what you injected. If you took significantly more than intended, call Poison Help at 1-800-222-1222 for guidance and watch for severe nausea, vomiting, dehydration, or hypoglycemia.

You can move tirzepatide products between the fridge and room temperature, but the label sets a total room-temperature clock — 21 days for single-dose pens and vials, 30 days for multi-dose vials and KwikPens. Refrigerating again does not reset that clock. Once the total is reached, discard.

No. Compounded drugs are made by compounding pharmacies and are not FDA-approved, do not undergo FDA premarket review, and don't go through FDA quality testing. They can be appropriate when there's a clinical reason, but they carry a higher safety bar than FDA-approved products.

For confirmed or suspected overdose, severe symptoms after a dose mistake (especially severe vomiting or hypoglycemia), or when you need a clinical professional on the phone right away. The number is 1-800-222-1222, free, 24/7. Per HRSA, callers reach a specially trained nurse, pharmacist, or doctor at their local poison center.

For voice and to feel less alone, sure. For dosing decisions, no. The person answering your question may be on a different brand, dose, schedule, device, or set of co-medications. Use Reddit and forums for emotional support and trend-spotting. Use the FDA labels and your prescriber for decisions.

What we actually verified

Primary sources

  • FDA prescribing information and IFUs for Wegovy (incl. Wegovy HD 7.2 mg, FDA-approved March 19, 2026) via DailyMed
  • FDA prescribing information and IFUs for Ozempic, Mounjaro, Zepbound (single-dose pens, single-dose vials, multi-dose vials, and KwikPens), Trulicity, and Saxenda via DailyMed
  • Manufacturer IFUs on wegovy.com, ozempic.com, saxenda.com, mounjaro.com, zepbound.com, and trulicity.com
  • FDA "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" page
  • FDA dosing-error safety communication on compounded injectable semaglutide products (originally published July 26, 2024)
  • FDA "Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize" statement
  • FDA proposal (April 30, 2026) regarding semaglutide, tirzepatide, and liraglutide on the 503B bulks list
  • CDC injection safety guidance ("One Needle, One Syringe, Only One Time")
  • FDA sharps disposal guidance
  • America's Poison Centers GLP-1 page
  • HRSA Poison Help description

What we did not do

  • • We did not run a clinical trial.
  • • We did not add a "medically reviewed by Dr. ___" badge — no individual clinician has signed off on the clinical content. The Tier 1 / Tier 2 / Tier 3 risk ranking is our editorial conclusion based on the three source buckets above. It is not a clinical trial finding.
  • • We did not pretend to have access to data we don't have.

Refresh schedule

Quarterly review. We re-check every FDA label, every storage rule, the FDA's compounded-GLP-1 enforcement status, and the manufacturer support numbers every three months — plus immediately after any major FDA safety communication. The "last verified" date at the top of this page updates when we recheck.

The shortest possible summary

Most GLP-1 injection mistakes don't matter much. The ones that do cluster in a small group: wrong dose from a compounded vial, frozen or out-of-storage pen, hitting muscle while on insulin or a sulfonylurea, and double-dosing because the first shot felt off. The fix for the dangerous mistakes is the same in every case: stop, don't inject again on assumption, check the pen's completion indicator, and call your prescriber, your pharmacist, the manufacturer, or Poison Help (1-800-222-1222) before you do anything else. The chart in this guide tells you the storage and missed-dose rule for the six FDA-approved injectable GLP-1s most people are searching about, plus compounded products. Bookmark it. The mistakes are predictable. The fixes are simple. The hardest part is the part where you don't panic and inject again.

Last verified May 7, 2026, against current FDA and DailyMed prescribing information and IFUs for Wegovy, Ozempic, Zepbound, Mounjaro, Trulicity, and Saxenda. Provider policies, FDA label language, and support numbers change. Re-verify monthly for drug-specific rules.

This page contains affiliate links. If you purchase through them, we may earn a commission at no extra cost to you. Clinical guidance is based on the FDA labels and authoritative sources cited above, not on commercial relationships.

This page is for general informational purposes and does not constitute medical advice. GLP-1 medications are prescription treatments. Consult your healthcare provider and pharmacist before making any clinical decisions based on this content.